Work

Cellular and in Vivo Activity of JNJ-28871063, A Nonquinazoline Pan-ErbB Kinase Inhibitor That Crosses the Blood-Brain Barrier and Displays Efficacy against Intracranial Tumors

Year: 2007

Type: article

Source: Molecular Pharmacology

DOI: 10.1124/mol.107.041236

Authors: Stuart L. Emanuel, Terry V. Hughes, Mary Adams, Catherine A. Rugg, Angel Fuentes-Pesquera, Peter J. Connolly, Niranjan Pandey, Sandra Moreno-Mazza, Jeannene Butler, Virna Borowski, Steven A. Middleton, Robert H. Gruninger, Jennifer R. Story, Cheryl Napier, Beth Hollister, Lee M. Greenberger

Institutions: Bristol-Myers Squibb (United States), Johnson & Johnson (United States), GlaxoSmithKline (United Kingdom), Celgene (United States), Sanofi (France), Merck & Co., Inc., Rahway, NJ, USA (United States), F. Hoffmann-La Roche AG, Enzon Pharmaceuticals (United States)

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2132722585

FWCI: 2.186

Cites: 59

Cited by: 37

Related to: 10